Prognostic significance of high expression of ER-beta in surgically treated ER-positive breast cancer following endocrine therapy

Journal of Breast Cancer

Volumn 15, Issue 1, 2012, Pages 79-86

  Kim, Tae Jung ^a   Lee, Ahwon ^a   Choi, Yeong Jin ^a   Song, Byung Joo ^a   Yim, Hyeon Woo ^a   Kang, Chang Suk ^a  

^a The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Breast neoplasms; Estrogen receptor; mRNA; Prognosis; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; ESTROGEN RECEPTOR BETA; MESSENGER RNA;

ADULT; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; PROGNOSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; TUMOR VOLUME;

EID: 84859359303     PISSN: 17386756     EISSN: None     Source Type: Journal    
DOI: 10.4048/jbc.2012.15.1.79     Document Type: Article

References (30)

1. Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 2008;113:2385-97
2. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;339:1609-18
3. Iwase H, Zhang Z, Omoto Y, Sugiura H, Yamashita H, Toyama T, et al. Clinical significance of the expression of estrogen receptors alpha and beta for endocrine therapy of breast cancer. Cancer Chemother Pharmacol 2003;52 Suppl 1:S34-8
4. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci U S A 1996;93:5925-30
5. Ogawa S, Inoue S, Watanabe T, Hiroi H, Orimo A, Hosoi T, et al. The complete primary structure of human estrogen receptor beta (hER beta) and its heterodimerization with ER alpha in vivo and in vitro. Biochem Biophys Res Commun 1998;243:122-6
6. Vladusic EA, Hornby AE, Guerra-Vladusic FK, Lupu R. Expression of estrogen receptor beta messenger RNA variant in breast cancer. Cancer Res 1998;58:210-4
7. Saunders PT, Millar MR, Williams K, Macpherson S, Bayne C, O'Sullivan C, et al. Expression of oestrogen receptor beta (ERbeta1) protein in human breast cancer biopsies. Br J Cancer 2002;86:250-6
8. Mann S, Laucirica R, Carlson N, Younes PS, Ali N, Younes A, et al. Estrogen receptor beta expression in invasive breast cancer. Hum Pathol 2001;32:113-8
9. Chae BJ, Bae JS, Yim HW, Lee A, Song BJ, Jeon HM, et al. Measurement of ER and PR status in breast cancer using the QuantiGene2.0 assay. Pathology 2011;43:248-53
10. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81
11. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131:18-43
12. Yim HW, Song BJ, Jung SS, Kim HJ, Choi YJ, Lee KY, et al. Branchedchain assay for ER, PR, and HER2 RNA levels is a useful adjunct in the evaluation of ER, PR, and HER2 in breast cancer. J Breast Cancer 2010; 13:267-74
13. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J Steroid Biochem Mol Biol 2006;102:89-96
14. Knight WA, Livingston RB, Gregory EJ, McGuire WL. Estrogen receptor as an independent prognostic factor for early recurrence in breast cancer. Cancer Res 1977;37:4669-71
15. Potemski P, Pluciennik E, Bednarek AK, Kusinska R, Kubiak R, Kordek R. Evaluation of oestrogen receptor expression in breast cancer by quantification of mRNA. Histopathology 2007;51:829-36
16. Jarzabek K, Koda M, Kozlowski L, Mittre H, Sulkowski S, Kottler ML, et al. Distinct mRNA, protein expression patterns and distribution of oestrogen receptors alpha and beta in human primary breast cancer: correlation with proliferation marker Ki-67 and clinicopathological factors. Eur J Cancer 2005;41:2924-34
17. Saji S, Hirose M, Toi M. Clinical significance of estrogen receptor beta in breast cancer. Cancer Chemother Pharmacol 2005;56 Suppl 1:21-6
18. Rosa FE, Caldeira JR, Felipes J, Bertonha FB, Quevedo FC, Domingues MA, et al. Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum Pathol 2008;39: 720-30
19. Myers E, Fleming FJ, Crotty TB, Kelly G, McDermott EW, O'Higgins NJ, et al. Inverse relationship between ER-beta and SRC-1 predicts outcome in endocrine-resistant breast cancer. Br J Cancer 2004;91:1687-93
20. Omoto Y, Kobayashi S, Inoue S, Ogawa S, Toyama T, Yamashita H, et al. Evaluation of oestrogen receptor beta wild-type and variant protein expression, and relationship with clinicopathological factors in breast cancers. Eur J Cancer 2002;38:380-6
21. Nakopoulou L, Lazaris AC, Panayotopoulou EG, Giannopoulou I, Givalos N, Markaki S, et al. The favourable prognostic value of oestrogen receptor beta immunohistochemical expression in breast cancer. J Clin Pathol 2004;57:523-8
22. Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, et al. Expression of estrogen receptor beta wild-type and its variant ERβcx/β2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 2007; 37:820-8
23. Chang HG, Kim SJ, Chung KW, Noh DY, Kwon Y, Lee ES, et al. Tamoxifen- resistant breast cancers show less frequent methylation of the estrogen receptor beta but not the estrogen receptor alpha gene. J Mol Med (Berl) 2005;83:132-9
24. Speirs V, Malone C, Walton DS, Kerin MJ, Atkin SL. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients. Cancer Res 1999;59:5421-4
25. Markey GC, Cullen R, Diggin P, Hill AD, Mc Dermott EW, O'Higgins NJ, et al. Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer. Tumour Biol 2009;30:171-5
26. Leygue E, Dotzlaw H, Watson PH, Murphy LC. Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res 1999;59:1175-9
27. Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, Lavaill R, Mollevi C, Warner M, et al. Estrogen receptor beta (ER beta) level but not its ER beta cx variant helps to predict tamoxifen resistance in breast cancer. Clin Cancer Res 2004;10:5769-76
28. Murphy LC, Leygue E, Niu Y, Snell L, Ho SM, Watson PH. Relationship of coregulator and oestrogen receptor isoform expression to de novo tamoxifen resistance in human breast cancer. Br J Cancer 2002;87:1411-6
29. Nicholson RI, McClelland RA, Robertson JF, Gee JM. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999;6:373-87
30. Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, et al. Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 2001;159:2249-56